Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use

Australian and New Zealand Journal of Psychiatry

Volumn 48, Issue 5, 2014, Pages 418-432

  Large, Matthew ^a,b   Mullin, Kate ^b   Gupta, Pal ^b   Harris, Anthony ^c   Nielssen, Olav ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cannabis; psychosis; schizophrenia; substance use

Indexed keywords

AFFECTIVE PSYCHOSIS; COMORBIDITY; HOSPITAL ADMISSION; HUMAN; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOCIAL STATUS; SUBSTANCE USE; VIOLENCE; COMPLICATION; DEPRESSION; HOSPITALIZATION; META ANALYSIS; ONSET AGE; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; PSYCHOTIC DISORDERS; RISK FACTOR; SELF-INJURIOUS BEHAVIOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; SYMPTOM ASSESSMENT;

AGE OF ONSET; DEPRESSION; DIAGNOSIS, DUAL (PSYCHIATRY); HOSPITALIZATION; HUMANS; PSYCHOTIC DISORDERS; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SUBSTANCE-RELATED DISORDERS; SYMPTOM ASSESSMENT;

EID: 84899894009     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414525838     Document Type: Review

References (61)

1. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. International Review of Psychiatry. 2010 ; 22: 417-428
2. Addington J, Addington D. Effect of substance misuse in early psychosis. British Journal of Psychiatry. Supplement. 1998 ; 172: 134-136
3. Andreasen NC, Arndt S, Miller D, et al. Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: An overview and update. Psychopathology. 1995 ; 28: 7-17
4. Andreasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987 ; ii: 1483-1486
5. Baeza I, Graell M, Moreno D, et al. Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research. 2009 ; 113: 129-137
6. Barnes TR, Mutsatsa SH, Hutton SB, et al. Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry. 2006 ; 188: 237-242
7. Barrowclough C, Emsley R, Eisner E, et al. Does change in cannabis use in established psychosis affect clinical outcome?. Schizophrenia Bulletin. 2013 ; 39: 339-348
8. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: Service utilization and costs. The Journal of Nervous and Mental Disease. 1993 ; 181: 227-232
9. Beck AT, Steer RT, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review. 1988 ; 8: 77-100
10. Birchwood M, Smith J, Cochrane R, et al. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. British Journal of Psychiatry. 1990 ; 157: 853-859
11. Borenstein B, Hedges LV, Higgins JTP, et al Introduction to Meta-Analysis. Chichester: Wiley ; 2009 :
12. Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among psychiatric outpatients: Focus on cognition, social role functioning, and psychiatric status. The Journal of Nervous and Mental Disease. 2003 ; 191: 300-308
13. Cuffel BJ, Chase P. Remission and relapse of substance use disorders in schizophrenia. Results from a one-year prospective study. The Journal of Nervous and Mental Disease. 1994 ; 182: 342-348
14. Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry. 2012 ; 72: 811-816
15. Di Forti M, Morrison PD, Butt A, et al. Cannabis use and psychiatric and cognitive disorders: The chicken or the egg?. Current Opinion in Psychiatry. 2007 ; 20: 228-234
16. Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. American Journal of Psychiatry. 1991 ; 148: 224-230
17. Faber G, Smid HG, Van Gool AR, et al. Continued cannabis use and outcome in first-episode psychosis: Data from a randomized, open-label, controlled trial. Journal of Clinical Psychiatry. 2012 ; 73: 632-638
18. Fowler IL, Carr VJ, Carter NT, et al. Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin. 1998 ; 24: 443-455
19. González-Pinto A, Alberich S, Barbeito S, et al. Cannabis and first-episode psychosis: Different long-term outcomes depending on continued or discontinued use. Schizophrenia Bulletin. 2011 ; 37: 631-639
20. Grech A, Van Os J, Jones PB, et al. Cannabis use and outcome of recent onset psychosis. European Psychiatry. 2005 ; 20: 349-353
21. Gupta P, Mullin K, Nielssen O, et al. Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 524-537
22. Hall W, Degenhardt L. Cannabis use and psychosis: A review of clinical and epidemiological evidence. Australian and New Zealand Journal of Psychiatry. 2000 ; 34: 26-34
23. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 1960 ; 23: 56-62
24. Harris AW, Large MM, Redoblado-Hodge A, et al. Clinical and cognitive associations with aggression in the first episode of psychosis. Australian and New Zealand Journal of Psychiatry. 2010 ; 44: 85-93
25. Harrison I, Joyce EM, Mutsatsa SH, et al. Naturalistic follow-up of co-morbid substance use in schizophrenia: The West London first-episode study. Psychological Medicine. 2008 ; 38: 79-88
26. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. British Medical Journal. 2003 ; 327: 557-560
27. Hinton M, Edwards J, Elkins K, et al. Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Intervention in Psychiatry. 2007 ; 1: 259-266
28. Kamali M, Kelly L, Gervin M, et al. The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia. Acta. Psychiatrica Scandinavica. 2000 ; 101: 452-456
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987 ; 13: 261-276
30. Kivlahan DR, Heiman JR, Wright RC, et al. Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse. Hospital & Community Psychiatry. 1991 ; 42: 609-614
31. Kovasznay B. Substance abuse among veterans with a diagnosis of schizophrenia. Hospital & Community Psychiatry. 1991 ; 42: 948-949
32. Large M, Sharma S, Compton MT, et al. Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Archives of General Psychiatry. 2011 ; 68: 555-561
33. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Medicine. 2009 ; 6: e1000100
34. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry. 2006 ; 40: 616-622
35. Maremmani I, Lazzeri A, Pacini M, et al. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. Journal of Psychoactive Drugs. 2004 ; 36: 235-241
36. Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychoses: Levels and consequences. Schizophrenia Research. 2004 ; 67: 157-166
37. Martinez-Arevalo MJ, Calcedo-Ordoñez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. British Journal of Psychiatry. 1994 ; 164: 679-681
38. Mauri MC, Volonteri LS, De Gaspari IF, et al. Substance abuse in first-episode schizophrenic patients: A retrospective study. Clinical Practice and Epidemiology in Mental Health. 2006 ; 2: 4
39. Monahan J, Steadman HJ, Appelbaum PS, et al. Developing a clinically useful actuarial tool for assessing violence risk. British Journal of Psychiatry. 2000 ; 176: 312-319
40. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007 ; 370: 319-328
41. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta. Psychiatrica Scandinavica. 2000 ; 101: 323-329
42. Mullin K, Gupta P, Compton MT, et al. Does giving up substance use work for patients with psychosis? A systematic meta-analysis. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 826-839
43. Negrete JC, Knapp WP. The effects of cannabis use on the clinical condition of schizophrenics. NIDA. Research Monograph. 1986 ; 67: 321-327
44. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962 ; 10: 799-812
45. Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine. 2006 ; 36: 431-440
46. Potvin S, Sepehry AA, Stip E. Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Australian and New Zealand Journal of Psychiatry. 2007 ; 41: 792-799
47. Rabinowitz J, Bromet EJ, Lavelle J, et al. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine. 1998 ; 28: 1411-1419
48. Riecher-Rössler A, Häfner H. Gender aspects in schizophrenia: Bridging the border between social and biological psychiatry. Acta Psychiatrica Scandinavica. Supplementum. 2000 ; (407). 58-62
49. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry. 1999 ; 56: 241-247
50. Rosenthal J. Qualitative descriptors of strength of association and effect size. Journal of Social Service Research. 1996 ; 21: 37-57
51. Sevy S, Robinson DG, Napolitano B, et al. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophrenia Research. 2010 ; 120: 101-107
52. Sorbara F, Liraud F, Assens F, et al. Substance use and the course of early psychosis: A 2-year follow-up of first-admitted subjects. European Psychiatry. 2003 ; 18: 133-136
53. Swendsen J, Ben-Zeev D, Granholm E. Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. American Journal of Psychiatry. 2011 ; 168: 202-209
54. Talamo A, Centorrino F, Tondo L, et al. Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. Schizophrenia Research. 2006 ; 86: 251-255
55. Turkington A, Mulholland CC, Rushe TM, et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. British Journal of Psychiatry. 2009 ; 195: 242-248
56. Van Dijk D, Koeter MW, Hijman R, et al. Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. Schizophrenia Research. 2012 ; 137: 50-57
57. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet. 2007 ; 370: 1453-1457
58. Wade D, Harrigan S, Edwards J, et al. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry. 2006 ; 189: 229-234
59. Wisdom JP, Manuel JI, Drake RE. Substance use disorder among people with first-episode psychosis: A systematic review of course and treatment. Psychiatric Services. 2011 ; 62: 1007-1012
60. Wobrock T, Falkai P, Schneider-Axmann T, et al. Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. Schizophrenia Research. 2013 ; 147: 132-139
61. Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin. 2012 ; 38: 316-330